Rockville, MD, United States
Rockville, MD, United States

Time filter

Source Type

News Article | May 9, 2017
Site: www.spie.org

Autonomous ozone, aerosol, and water vapor profiling of the atmosphere The Autonomous Mobile Ozone Lidar Instrument for Tropospheric Experiments is used to obtain atmospheric profiles from near to the ground to altitudes of more than 10km. Tropospheric ozone, aerosols, and water vapor are important atmospheric constituents that affect air quality and climate. For instance, ozone is a short-lived climate pollutant that is photochemically active with nitrogen oxides, and its concentration in the troposphere can be significantly increased by stratospheric–tropospheric exchange events. In addition, aerosols contribute to the radiative budget, are a tracer for pollution transport, and they affect visibility, cloud formation, and air quality. Lastly, water vapor plays a pivotal role in climate change and atmospheric stability because it influences many atmospheric processes (e.g., cloud formation and photochemical atmospheric reactions). It is therefore important to measure the abundance of these atmospheric components in a synergistic way, to support the development of air-quality forecasts and diagnostic models. Such measurements can also be used for validating satellite observations that provide a regional to global perspective. Lidar (light detection and ranging) technology has rapidly advanced over the past several decades. From a number of different platforms, this technique can now be used to measure a variety of atmospheric constituents with ever increasing accuracy and at ever finer scales. Although the number of lidar instruments continues to increase worldwide, these platforms generally require an operator (particularly high-powered lidar systems).1, 2 To overcome the need for a lidar operator, our team at Environment and Climate Change Canada (ECCC) have previously designed several autonomous aerosol lidar systems3 to support a number of research objectives. For example, we have recently developed an autonomous mobile lidar system (see Figure 1) that is known as the Autonomous Mobile Ozone Lidar Instrument for Tropospheric Experiments (AMOLITE).4 With this system, we build upon the successes of our earlier autonomous lidars, but we now use a synergistic approach to simultaneously measure the vertical profiles of tropospheric ozone, aerosols, and water vapor. Within the AMOLITE design (see Figure 2) we combine a dual laser for redundancy purposes and a dual lidar design, i.e., the tropospheric ozone Differential Absorption lidar (DIAL) and an aerosol lidar with three backscatter channels, two Raman channels, and one cross-polarization channel (‘3+2+1’ configuration). In addition, we have added a water vapor channel—arising from the Raman-shifted 355nm output (407nm)—to provide nighttime water vapor profiles. The final product of our system is lidar profiles (near-ground to 10–15km altitude) at minute-long intervals. Our system is operated remotely 24 hours a day, seven days a week (except during precipitation events). Furthermore, the data are updated hourly to a website, thus enabling near-real-time analysis. Figure 1. Photograph of the Autonomous Mobile Ozone Lidar Instrument for Tropospheric Experiments (AMOLITE) mounted in a climate-controlled mobile trailer. Figure 2. Schematic of the transmitter layout of the AMOLITE optical bench. The design includes the Differential Absorption lidar (DIAL) and a dual laser design for each lidar transmitter assembly. The 266nm laser light is Raman-shifted with the use of a 1m-long carbon dioxide Raman cell. Schematic of the transmitter layout of the AMOLITE optical bench. The design includes the Differential Absorption lidar (DIAL) and a dual laser design for each lidar transmitter assembly. The 266nm laser light is Raman-shifted with the use of a 1m-long carbon dioxide Raman cell. 5 Figure 3. Plots of (a) the ozone mixing ratio in parts per billion volume (ppbv), (b) the 532nm backscatter ratio, and (c) the water vapor mixing ratio in g/kg obtained simultaneously from AMOLITE during a 15-hour period on 23–24 June 2016 (local time is shown). These measurements were obtained as part of the instrument's testing phase. Water vapor measurements were only obtained at night. Figure 4. Plot of the ozone (O ) mixing ratio from near to the ground to an altitude of 13.5km above sea level (asl). These AMOLITE observations were obtained at the Jet Propulsion Laboratory's Table Mountain Facility in Wrightwood, CA (2270m asl) between 9 August and 7 September 2016. White regions in the plot are where no data was obtained because of cloud cover, brief system downtime, or very low signal-to-noise data (daytime). The system performance is reduced during the day because of higher signal background levels. Figure 5. Results from the Southern California Ozone Observation Project (SCOOP). Left: Ozone profiles obtained with AMOLITE and from an ozone sonde on 15 August 2016 at 15:30 coordinated universal time. Center: The percentage difference between the AMOLITE and sonde profiles (vertical lines represent 10% uncertainty). Right: The horizontal geophysical separation between the sonde and AMOLITE. At higher altitudes there is less agreement between the sonde and AMOLITE ozone measurements because of the increased separation. Both of the lidars in AMOLITE are mounted in a climate-controlled mobile trailer that has a sophisticated ‘artificial intelligence’ system. In this way, we are able to remotely operate the trailer in a variety of environmental and operational conditions. We also rely on a modified aircraft-detecting radar system to achieve autonomous operation. This radar system automatically detects aircraft within the nominal hazard zone (NHZ) of the laser beam and stops laser emission until the aircraft leaves the NHZ. Full details of our autonomous system have been published previously.3 The true novelty of our autonomous system is that it provides the opportunity to explore the synergy of simultaneously obtained lidar-derived profiles of ozone, aerosols, and water vapor. An example of our three-product data (obtained over a 15-hour period during 23–24 June 2016) is shown in Figure 3. These observations exhibit a substantial amount of correlation and anti-correlation between the three plots. The results show that the concentrated aerosol layer at an altitude of about 4km—see Figure 3(b)—has ozone values of 80–90 parts per billion volume (ppbv)—see Figure 3(a)—whereas the boundary layer ozone has values of about 30ppbv (except for the local ozone plume below 500m during an eight-hour period). In addition, the water vapor profile in Figure 3(c) shows a well-mixed residual layer with values of about 15g/kg, except for a one-hour period of drier air around midnight. The water vapor plot does not indicate that the concentrated aerosol layer is moist. We also show a 30-day consecutive curtain plot of tropospheric ozone in Figure 4. This data set immediately illustrates the advantage of an autonomous system, i.e., it provides a quick look at many different regimes and processes, along with the atmospheric variability during the observation period. In addition, the water vapor plots we obtain (not shown) allow us to identify stratospheric intrusions because the dry air from the stratosphere correlates well with the high ozone concentrations we observe (another advantage of simultaneously measuring multiple lidar products). We have evaluated the performance of our AMOLITE ozone lidar through an intercomparison study—with four other tropospheric ozone lidar systems, all of which are part of the Tropospheric Ozone Lidar Network6 (TOLNet). We conducted this study—known as the Southern California Ozone Observation Project (SCOOP)—at the Jet Propulsion Laboratory's Table Mountain Facility in Wrightwood, CA. It provided us with the opportunity to compare lidar ozone profiles obtained with AMOLITE and with lidar instruments on 18 ozone sondes that were launched during the study. Our results (see Figure 5) show that there is a good level of agreement between our AMOLITE measurements and those from the ozone sondes. In summary, we have developed AMOLITE as an autonomous mobile lidar system to reduce the need for an operator when making atmospheric lidar measurements. We have successfully tested our system and its ability to obtain vertical profiles of ozone, aerosols, and water vapor (from near to the ground to an altitude of about 15km). We have also demonstrated that our system provides measurements with a high level of agreement to those obtained from ozone sondes. In the next steps of our work we plan to add a small telescope to our ozone DIAL system. This will reduce the minimum altitude from which we can retrieve ozone concentrations (from 400m to about 150m). We will also deploy AMOLITE in northern Alberta (Canada), where it will be part of a ‘supersite’ of instrumentation (i.e., a complex suite of in situ chemistry instruments). Air Quality Processes Research Section Environment and Climate Change Canada Kevin Strawbridge has a PhD in physics and is a senior research scientist in the Processes Research Section of the Science and Technology Branch, where he leads the Lidar group. He is known nationally and internationally for his development of a variety of lidar systems, including two aircraft instruments, a mobile scanning lidar laboratory, as well as various ground-based zenith-pointing lidar systems. He has served on several international committees and continues to provide leadership in his field of research. His main research interests are directed at understanding the optical and chemical properties, as well as the transport mechanisms of aerosols and ozone, in addition to their influence on climate, visibility, and air quality. 1. R. J. Alvarez, C. J. Senff, A. O. Langford, A. M. Weickmann, D. C. Law, J. L. Machol, D. A. Merritt, et al., Development and application of a compact, tunable, solid-state airborne ozone lidar system for boundary layer profiling, J. Atmos. Ocean. Technol. 28, p. 1258-1272, 2011. 2. J. T. Sullivan, T. J. McGee, G. K. Sumnicht, L. W. Twigg, R. M. Hoff, A mobile differential absorption lidar to measure sub-hourly fluctuation of tropospheric ozone profiles in the Baltimore--Washington, D.C. region, Atmos. Meas. Tech. 7, p. 3529-3548, 2014. 4. K. B. Strawbridge, Autonomous ozone and aerosol lidar profiling of the troposphere: first results. Presented at SPIE Remote Sensing 2016.


WATERTOWN, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced new preclinical data regarding non-immunogenic gene therapies that were presented at the American Society of Gene & Cell Therapy (ASGCT) 2017 Annual Meeting, which took place last week in Washington, D.C. “Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “Together with various collaborators, we have again demonstrated the potential of Selecta’s proprietary immune tolerance Synthetic Vaccine Particles (SVP™) technology, which is designed to improve the clinical benefits and transform the development of gene therapy. We also were pleased with the presentation of preclinical proof-of-concept data for our proprietary product candidate in MMA, a life-threatening rare disease that can only be treated today by diet or organ transplantation.” A team led by Charles Venditti, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the National Human Genome Research Institute at the National Institutes of Health, and Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Mass. Eye and Ear and an Assistant Professor at Harvard Medical School, delivered a presentation entitled “Anc80 Mediates Hepatic Correction of Methylmalonyl-CoA Mutase Deficiency in Murine Models of Methymalonic Acidemia.” This presentation featured data from mouse models of MMA, a rare inborn error of metabolism most frequently caused by mutations in the enzyme methylmalonyl-CoA mutase (MUT). In this study, MUT-deficient mice were treated with Selecta’s Anc80-synMUT product candidate to express the human MUT gene. The gene therapy induced a robust biochemical and clinical response as plasma methylmalonic acid levels dropped precipitously, substantial weight gain ensued and survival was sustained. Further, presented data indicate that the combination of SVP and Anc80 could effectively overcome the immunogenicity that has limited other gene therapy programs by enabling enrollment of patients with pre-existing antibodies to AAV and keeping patients eligible for repeat administration. A team led by Federico Mingozzi, Ph.D., Head of Immunology and Liver Gene Therapy at Genethon, delivered a presentation entitled “Modulation of AAV Vector Dosing and Avoidance of Capsid Immune Responses via Repeated Co-Administration of Vector with Rapamycin Tolerogenic Nanoparticles.” This presentation featured data from both mouse and non-human primate studies demonstrating how the co-administration of SVP-Rapamycin completely blocked anti-AAV immune responses in an antigen-specific manner and allowed for vector re-administration and gene therapy dose titration. The ability to dose titrate could provide for more effective development and administration of gene therapies. Click here to view these presentations. MMA is an inborn error of metabolism that, according to the U.S. National Institutes of Health (NIH), affects an estimated one in 25,000 to 48,000 individuals globally. MMA patients are unable to process certain proteins and fats, leading to the accumulation of toxic metabolites. Symptoms of this life-threatening disease start to develop in early childhood and, despite strict diet, patients suffer from a wide range of disease-related complications such as pancreatitis, strokes and chronic kidney failure. Selecta exclusively licensed Anc80 for MMA from Massachusetts Eye and Ear® (MEE) in May 2016. Under the license agreement, Selecta also has the exclusive option to develop gene therapies using Anc80 for additional pre-defined lysosomal storage, genetic muscular and genetic metabolic diseases. In early 2017, Selecta entered into a strategic manufacturing agreement with Lonza Houston, Inc. under which Lonza will produce an Anc80-AAV-based gene therapy product for Selecta's MMA program. Selecta intends to combine Anc80 with recently discovered transgenes and Selecta’s SVP-Rapamycin to create a novel gene therapy for MMA. This therapy is intended to a) enable the treatment of patients with and without pre-existing anti-AAV antibodies; b) prevent cellular immune responses that often reduce the expression levels of gene therapies; and c) provide the ability to administer repeat gene therapy doses to achieve sufficient levels of methylmalonyl-CoA mutase (MUT), the enzyme that MMA patients are lacking. To advance the MMA program, Selecta entered into a Collaborative Research and Development Agreement (CRADA) with MEE and the National Human Genome Research Institute, NIH, in 2016. Principal investigators in this CRADA initiative are Charles Venditti, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the National Human Genome Research Institute at the National Institutes of Health, and Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at MEE and an Assistant Professor at Harvard Medical School. A physician-scientist specializing in the study of inborn errors of metabolism including MMA, Dr. Venditti and his group have published several studies showing the effectiveness of gene therapy as a treatment for MMA in mice. Dr. Vandenberghe from MEE is the inventor of Anc80. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter. Forward-Looking Statements Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, whether the company’s MMA product candidate will prevent cellular immune responses, enable repeat administration or allow for the treatment of patients with and without pre-existing anti-AAV antibodies, the company’s ability to unlock the full potential of biologic therapies, the company’s plan to apply its SVP platform to a range of biologics for rare and serious diseases, the potential of SEL-212 to treat severe gout patients and resolve their debilitating symptoms, the potential of the company’s two gene therapy product candidates to enable repeat administration, the potential treatment applications for products utilizing the SVP platform in areas such as gene therapy, immuno-oncology, allergies, autoimmune diseases and vaccines, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 11, 2017, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.


WATERTOWN, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced new preclinical data regarding non-immunogenic gene therapies that were presented at the American Society of Gene & Cell Therapy (ASGCT) 2017 Annual Meeting, which took place last week in Washington, D.C. “Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “Together with various collaborators, we have again demonstrated the potential of Selecta’s proprietary immune tolerance Synthetic Vaccine Particles (SVP™) technology, which is designed to improve the clinical benefits and transform the development of gene therapy. We also were pleased with the presentation of preclinical proof-of-concept data for our proprietary product candidate in MMA, a life-threatening rare disease that can only be treated today by diet or organ transplantation.” A team led by Charles Venditti, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the National Human Genome Research Institute at the National Institutes of Health, and Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Mass. Eye and Ear and an Assistant Professor at Harvard Medical School, delivered a presentation entitled “Anc80 Mediates Hepatic Correction of Methylmalonyl-CoA Mutase Deficiency in Murine Models of Methymalonic Acidemia.” This presentation featured data from mouse models of MMA, a rare inborn error of metabolism most frequently caused by mutations in the enzyme methylmalonyl-CoA mutase (MUT). In this study, MUT-deficient mice were treated with Selecta’s Anc80-synMUT product candidate to express the human MUT gene. The gene therapy induced a robust biochemical and clinical response as plasma methylmalonic acid levels dropped precipitously, substantial weight gain ensued and survival was sustained. Further, presented data indicate that the combination of SVP and Anc80 could effectively overcome the immunogenicity that has limited other gene therapy programs by enabling enrollment of patients with pre-existing antibodies to AAV and keeping patients eligible for repeat administration. A team led by Federico Mingozzi, Ph.D., Head of Immunology and Liver Gene Therapy at Genethon, delivered a presentation entitled “Modulation of AAV Vector Dosing and Avoidance of Capsid Immune Responses via Repeated Co-Administration of Vector with Rapamycin Tolerogenic Nanoparticles.” This presentation featured data from both mouse and non-human primate studies demonstrating how the co-administration of SVP-Rapamycin completely blocked anti-AAV immune responses in an antigen-specific manner and allowed for vector re-administration and gene therapy dose titration. The ability to dose titrate could provide for more effective development and administration of gene therapies. Click here to view these presentations. MMA is an inborn error of metabolism that, according to the U.S. National Institutes of Health (NIH), affects an estimated one in 25,000 to 48,000 individuals globally. MMA patients are unable to process certain proteins and fats, leading to the accumulation of toxic metabolites. Symptoms of this life-threatening disease start to develop in early childhood and, despite strict diet, patients suffer from a wide range of disease-related complications such as pancreatitis, strokes and chronic kidney failure. Selecta exclusively licensed Anc80 for MMA from Massachusetts Eye and Ear® (MEE) in May 2016. Under the license agreement, Selecta also has the exclusive option to develop gene therapies using Anc80 for additional pre-defined lysosomal storage, genetic muscular and genetic metabolic diseases. In early 2017, Selecta entered into a strategic manufacturing agreement with Lonza Houston, Inc. under which Lonza will produce an Anc80-AAV-based gene therapy product for Selecta's MMA program. Selecta intends to combine Anc80 with recently discovered transgenes and Selecta’s SVP-Rapamycin to create a novel gene therapy for MMA. This therapy is intended to a) enable the treatment of patients with and without pre-existing anti-AAV antibodies; b) prevent cellular immune responses that often reduce the expression levels of gene therapies; and c) provide the ability to administer repeat gene therapy doses to achieve sufficient levels of methylmalonyl-CoA mutase (MUT), the enzyme that MMA patients are lacking. To advance the MMA program, Selecta entered into a Collaborative Research and Development Agreement (CRADA) with MEE and the National Human Genome Research Institute, NIH, in 2016. Principal investigators in this CRADA initiative are Charles Venditti, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the National Human Genome Research Institute at the National Institutes of Health, and Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at MEE and an Assistant Professor at Harvard Medical School. A physician-scientist specializing in the study of inborn errors of metabolism including MMA, Dr. Venditti and his group have published several studies showing the effectiveness of gene therapy as a treatment for MMA in mice. Dr. Vandenberghe from MEE is the inventor of Anc80. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter. Forward-Looking Statements Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, whether the company’s MMA product candidate will prevent cellular immune responses, enable repeat administration or allow for the treatment of patients with and without pre-existing anti-AAV antibodies, the company’s ability to unlock the full potential of biologic therapies, the company’s plan to apply its SVP platform to a range of biologics for rare and serious diseases, the potential of SEL-212 to treat severe gout patients and resolve their debilitating symptoms, the potential of the company’s two gene therapy product candidates to enable repeat administration, the potential treatment applications for products utilizing the SVP platform in areas such as gene therapy, immuno-oncology, allergies, autoimmune diseases and vaccines, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 11, 2017, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.


WATERTOWN, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced new preclinical data regarding non-immunogenic gene therapies that were presented at the American Society of Gene & Cell Therapy (ASGCT) 2017 Annual Meeting, which took place last week in Washington, D.C. “Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “Together with various collaborators, we have again demonstrated the potential of Selecta’s proprietary immune tolerance Synthetic Vaccine Particles (SVP™) technology, which is designed to improve the clinical benefits and transform the development of gene therapy. We also were pleased with the presentation of preclinical proof-of-concept data for our proprietary product candidate in MMA, a life-threatening rare disease that can only be treated today by diet or organ transplantation.” A team led by Charles Venditti, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the National Human Genome Research Institute at the National Institutes of Health, and Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Mass. Eye and Ear and an Assistant Professor at Harvard Medical School, delivered a presentation entitled “Anc80 Mediates Hepatic Correction of Methylmalonyl-CoA Mutase Deficiency in Murine Models of Methymalonic Acidemia.” This presentation featured data from mouse models of MMA, a rare inborn error of metabolism most frequently caused by mutations in the enzyme methylmalonyl-CoA mutase (MUT). In this study, MUT-deficient mice were treated with Selecta’s Anc80-synMUT product candidate to express the human MUT gene. The gene therapy induced a robust biochemical and clinical response as plasma methylmalonic acid levels dropped precipitously, substantial weight gain ensued and survival was sustained. Further, presented data indicate that the combination of SVP and Anc80 could effectively overcome the immunogenicity that has limited other gene therapy programs by enabling enrollment of patients with pre-existing antibodies to AAV and keeping patients eligible for repeat administration. A team led by Federico Mingozzi, Ph.D., Head of Immunology and Liver Gene Therapy at Genethon, delivered a presentation entitled “Modulation of AAV Vector Dosing and Avoidance of Capsid Immune Responses via Repeated Co-Administration of Vector with Rapamycin Tolerogenic Nanoparticles.” This presentation featured data from both mouse and non-human primate studies demonstrating how the co-administration of SVP-Rapamycin completely blocked anti-AAV immune responses in an antigen-specific manner and allowed for vector re-administration and gene therapy dose titration. The ability to dose titrate could provide for more effective development and administration of gene therapies. Click here to view these presentations. MMA is an inborn error of metabolism that, according to the U.S. National Institutes of Health (NIH), affects an estimated one in 25,000 to 48,000 individuals globally. MMA patients are unable to process certain proteins and fats, leading to the accumulation of toxic metabolites. Symptoms of this life-threatening disease start to develop in early childhood and, despite strict diet, patients suffer from a wide range of disease-related complications such as pancreatitis, strokes and chronic kidney failure. Selecta exclusively licensed Anc80 for MMA from Massachusetts Eye and Ear® (MEE) in May 2016. Under the license agreement, Selecta also has the exclusive option to develop gene therapies using Anc80 for additional pre-defined lysosomal storage, genetic muscular and genetic metabolic diseases. In early 2017, Selecta entered into a strategic manufacturing agreement with Lonza Houston, Inc. under which Lonza will produce an Anc80-AAV-based gene therapy product for Selecta's MMA program. Selecta intends to combine Anc80 with recently discovered transgenes and Selecta’s SVP-Rapamycin to create a novel gene therapy for MMA. This therapy is intended to a) enable the treatment of patients with and without pre-existing anti-AAV antibodies; b) prevent cellular immune responses that often reduce the expression levels of gene therapies; and c) provide the ability to administer repeat gene therapy doses to achieve sufficient levels of methylmalonyl-CoA mutase (MUT), the enzyme that MMA patients are lacking. To advance the MMA program, Selecta entered into a Collaborative Research and Development Agreement (CRADA) with MEE and the National Human Genome Research Institute, NIH, in 2016. Principal investigators in this CRADA initiative are Charles Venditti, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the National Human Genome Research Institute at the National Institutes of Health, and Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at MEE and an Assistant Professor at Harvard Medical School. A physician-scientist specializing in the study of inborn errors of metabolism including MMA, Dr. Venditti and his group have published several studies showing the effectiveness of gene therapy as a treatment for MMA in mice. Dr. Vandenberghe from MEE is the inventor of Anc80. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter. Forward-Looking Statements Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, whether the company’s MMA product candidate will prevent cellular immune responses, enable repeat administration or allow for the treatment of patients with and without pre-existing anti-AAV antibodies, the company’s ability to unlock the full potential of biologic therapies, the company’s plan to apply its SVP platform to a range of biologics for rare and serious diseases, the potential of SEL-212 to treat severe gout patients and resolve their debilitating symptoms, the potential of the company’s two gene therapy product candidates to enable repeat administration, the potential treatment applications for products utilizing the SVP platform in areas such as gene therapy, immuno-oncology, allergies, autoimmune diseases and vaccines, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 11, 2017, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.


WATERTOWN, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced new preclinical data regarding non-immunogenic gene therapies that were presented at the American Society of Gene & Cell Therapy (ASGCT) 2017 Annual Meeting, which took place last week in Washington, D.C. “Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “Together with various collaborators, we have again demonstrated the potential of Selecta’s proprietary immune tolerance Synthetic Vaccine Particles (SVP™) technology, which is designed to improve the clinical benefits and transform the development of gene therapy. We also were pleased with the presentation of preclinical proof-of-concept data for our proprietary product candidate in MMA, a life-threatening rare disease that can only be treated today by diet or organ transplantation.” A team led by Charles Venditti, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the National Human Genome Research Institute at the National Institutes of Health, and Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Mass. Eye and Ear and an Assistant Professor at Harvard Medical School, delivered a presentation entitled “Anc80 Mediates Hepatic Correction of Methylmalonyl-CoA Mutase Deficiency in Murine Models of Methymalonic Acidemia.” This presentation featured data from mouse models of MMA, a rare inborn error of metabolism most frequently caused by mutations in the enzyme methylmalonyl-CoA mutase (MUT). In this study, MUT-deficient mice were treated with Selecta’s Anc80-synMUT product candidate to express the human MUT gene. The gene therapy induced a robust biochemical and clinical response as plasma methylmalonic acid levels dropped precipitously, substantial weight gain ensued and survival was sustained. Further, presented data indicate that the combination of SVP and Anc80 could effectively overcome the immunogenicity that has limited other gene therapy programs by enabling enrollment of patients with pre-existing antibodies to AAV and keeping patients eligible for repeat administration. A team led by Federico Mingozzi, Ph.D., Head of Immunology and Liver Gene Therapy at Genethon, delivered a presentation entitled “Modulation of AAV Vector Dosing and Avoidance of Capsid Immune Responses via Repeated Co-Administration of Vector with Rapamycin Tolerogenic Nanoparticles.” This presentation featured data from both mouse and non-human primate studies demonstrating how the co-administration of SVP-Rapamycin completely blocked anti-AAV immune responses in an antigen-specific manner and allowed for vector re-administration and gene therapy dose titration. The ability to dose titrate could provide for more effective development and administration of gene therapies. Click here to view these presentations. MMA is an inborn error of metabolism that, according to the U.S. National Institutes of Health (NIH), affects an estimated one in 25,000 to 48,000 individuals globally. MMA patients are unable to process certain proteins and fats, leading to the accumulation of toxic metabolites. Symptoms of this life-threatening disease start to develop in early childhood and, despite strict diet, patients suffer from a wide range of disease-related complications such as pancreatitis, strokes and chronic kidney failure. Selecta exclusively licensed Anc80 for MMA from Massachusetts Eye and Ear® (MEE) in May 2016. Under the license agreement, Selecta also has the exclusive option to develop gene therapies using Anc80 for additional pre-defined lysosomal storage, genetic muscular and genetic metabolic diseases. In early 2017, Selecta entered into a strategic manufacturing agreement with Lonza Houston, Inc. under which Lonza will produce an Anc80-AAV-based gene therapy product for Selecta's MMA program. Selecta intends to combine Anc80 with recently discovered transgenes and Selecta’s SVP-Rapamycin to create a novel gene therapy for MMA. This therapy is intended to a) enable the treatment of patients with and without pre-existing anti-AAV antibodies; b) prevent cellular immune responses that often reduce the expression levels of gene therapies; and c) provide the ability to administer repeat gene therapy doses to achieve sufficient levels of methylmalonyl-CoA mutase (MUT), the enzyme that MMA patients are lacking. To advance the MMA program, Selecta entered into a Collaborative Research and Development Agreement (CRADA) with MEE and the National Human Genome Research Institute, NIH, in 2016. Principal investigators in this CRADA initiative are Charles Venditti, M.D., Ph.D., Senior Investigator and Head, Organic Acid Research Section in the National Human Genome Research Institute at the National Institutes of Health, and Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at MEE and an Assistant Professor at Harvard Medical School. A physician-scientist specializing in the study of inborn errors of metabolism including MMA, Dr. Venditti and his group have published several studies showing the effectiveness of gene therapy as a treatment for MMA in mice. Dr. Vandenberghe from MEE is the inventor of Anc80. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter. Forward-Looking Statements Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, whether the company’s MMA product candidate will prevent cellular immune responses, enable repeat administration or allow for the treatment of patients with and without pre-existing anti-AAV antibodies, the company’s ability to unlock the full potential of biologic therapies, the company’s plan to apply its SVP platform to a range of biologics for rare and serious diseases, the potential of SEL-212 to treat severe gout patients and resolve their debilitating symptoms, the potential of the company’s two gene therapy product candidates to enable repeat administration, the potential treatment applications for products utilizing the SVP platform in areas such as gene therapy, immuno-oncology, allergies, autoimmune diseases and vaccines, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 11, 2017, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.


News Article | November 30, 2016
Site: www.acnnewswire.com

- Scholarship quiz show, called "Janghak Quiz", on the major educational television network in Korea - AI solutions to be developed for legal, patent and counseling areas Exobrain, a language intelligence software for communicating between human and machine developed by the Electronics and Telecommunications Research Institute (ETRI), defeated four human champions in a quiz show on EBS Korea. South Korea's Educational Broadcasting System is a children's educational television and radio network. On November 18 Exobrain went "head-to-head" with human competitors on the television quiz show, "Janghak Quiz", which was recorded at the ETRI auditorium. Exobrain outpaced all competitors by scoring 510 out of 600 points, providing correct answers for 25 questions out of 30 (10 multiple-choice and 20 short-answer questions). The Exobrain defeated four human quiz prodigies: Mr. Yun Ju-il (finishing in 2nd place), a freshman of Seoul National University who attained a perfect score in last year's national college entrance exam; Mr. Kim Hyeon-ho and Miss Lee Jeong-min, the champions of the "Janghak Quiz" in the first and second half of 2016, respectively; and Mr. Oh Hyeon-min, who is studying mathematical sciences at KAIST and demonstrated his outstanding intelligence in a televised brain game. Here's how Exobrain works: once a question is given, the system first derives keywords. For instance, in response to the question: "What is the stone tablet found in Egypt and described in Empire of the Ants, a novel written by Bernard Werber, which enabled communication between humans and ants?", the AI system searches such keywords as Werber, ants, communication, stone tablet and Egypt from its database before filtering tens to hundreds of possible answers. Next, it measures each potential answer against the question, assessing the reliability of each answer and finally submitting the most reliable answer. It only takes six to seven seconds to work out an answer. In the quiz contest, Exobrain dominated the human competitors, but the system did not get all the answers right. The research team explained that Exobrain made a few wrong answers because some questions were related to fields the system had not learned about yet and the system did not have sufficient data to infer correct answers. The team added that further research and development would be required to conduct a semantic analysis of languages. According to ETRI, the core artificial intelligence (AI) technologies of Exobrain are: Korean language analysis technology, to analyze the grammar rules applied to sentences as its human counterparts can do; knowledge acquisition and exploration technology, to learn and store linguistic knowledge and unit of knowledge (a subject-predicate-object structure) from vast amount of books, documents, Wikipedia articles, dictionaries, and so on; and natural language QA technology, to understand questions comprising multiple sentences and infer answers. The quiz contest was intended to verify the level of first-stage technology developed over the first four years of the 10-year research period. The second and third stages of research are scheduled to be completed by 2022. For phase two, ETRI plans to focus on developing applied technologies and achieving globally competitive performance of QA solutions for expert knowledge including counseling, legal and patent areas. The last phase of the project will focus on developing QA solutions for expert knowledge in both Korean and English so that the AI system can engage in QA activities regarding expert knowledge described in English. In addition, ETRI researchers are committed to developing QA solutions for AI robots and wearable devices that can be utilized with a range of smart devices. Currently, Exobrain shows a level of performance similar to that of Watson, the AI system developed by IBM. In 2011, Watson appeared on the CBS quiz show "Jeopardy!" and defeated human quiz champions. Through further development, this AI system is now supporting the decision-making processes of medical, financial, and legal professionals. ETRI aims to commercialize Exobrain within the next three years. Exobrain will be used to conduct prior analysis of areas requiring revision of law in partnership with the National Assembly Library, and the AI system is also expected to be used for filtering overlapping technologies in the process of screening patent applications. "The correct answer rate of Exobrain is 83% on average, which is higher than Watson's performance (70%) in 2011," says Dr. Dong Won Han, Vice President of ETRI, SW and Contents Research Laboratory. "Considering that Exobrain was originally developed for the Korean language, it will have further potential uses when it is upgraded." About ETRI Established in 1976, ETRI is a non-profit Korean government-funded research organization that has been at the forefront of technological excellence for about 40 years. In the 1980s, ETRI developed TDX (Time Division Exchange) and 4M DRAM. In the 1990s, ETRI commercialized CDMA (Code Division Multiple Access) for the first time in the world. In the 2000s, ETRI developed Terrestrial DMB, WiBro, and 4G LTE Advanced, which became the foundation of mobile communications. Recently, as a global ICT leader, ETRI has been advancing communication and convergence by developing SAN (Ship Area Network) technology, Genie Talk (world class portable automatic interpretation; Korean-English/Japanese/Chinese), and automated valet parking technology. As of 2016, ETRI has about 2,000 employees where about 1,800 of them are researchers. For more informatoin, please visit https://www.etri.re.kr/eng/main/main.etri For more information, please contact Dr. Hyun-ki Kim Director, Knowledge Mining Research Section, ETRI e-mail: phone: +82 42 860 5965 Press release distributed by ResearchSEA on behalf of ETRI. Topic: Research and development Sectors: Electronics, IT Individual, Science & Research http://www.acnnewswire.com From the Asia Corporate News Network


News Article | November 30, 2016
Site: www.newsmaker.com.au

Daejeon, KOREA - Exobrain, a language intelligence software for communicating between human and machine developed by the Electronics and Telecommunications Research Institute (ETRI), defeated four human champions in a quiz show on EBS Korea. South Korea's Educational Broadcasting System is a children's educational television and radio network. On November 18 Exobrain went "head-to-head" with human competitors on the television quiz show, "Janghak Quiz", which was recorded at the ETRI auditorium. Exobrain outpaced all competitors by scoring 510 out of 600 points, providing correct answers for 25 questions out of 30 (10 multiple-choice and 20 short-answer questions). The Exobrain defeated four human quiz prodigies: Mr. Yun Ju-il (finishing in 2nd place), a freshman of Seoul National University who attained a perfect score in last year's national college entrance exam; Mr. Kim Hyeon-ho and Miss Lee Jeong-min, the champions of the "Janghak Quiz" in the first and second half of 2016, respectively; and Mr. Oh Hyeon-min, who is studying mathematical sciences at KAIST and demonstrated his outstanding intelligence in a televised brain game.  Here's how Exobrain works: once a question is given, the system first derives keywords. For instance, in response to the question: "What is the stone tablet found in Egypt and described in Empire of the Ants, a novel written by Bernard Werber, which enabled communication between humans and ants?", the AI system searches such keywords as Werber, ants, communication, stone tablet and Egypt from its database before filtering tens to hundreds of possible answers. Next, it measures each potential answer against the question, assessing the reliability of each answer and finally submitting the most reliable answer. It only takes six to seven seconds to work out an answer.  In the quiz contest, Exobrain dominated the human competitors, but the system did not get all the answers right. The research team explained that Exobrain made a few wrong answers because some questions were related to fields the system had not learned about yet and the system did not have sufficient data to infer correct answers. The team added that further research and development would be required to conduct a semantic analysis of languages. According to ETRI, the core artificial intelligence (AI) technologies of Exobrain are: Korean language analysis technology, to analyze the grammar rules applied to sentences as its human counterparts can do; knowledge acquisition and exploration technology, to learn and store linguistic knowledge and unit of knowledge (a subject-predicate-object structure) from vast amount of books, documents, Wikipedia articles, dictionaries, and so on; and natural language QA technology, to understand questions comprising multiple sentences and infer answers. The quiz contest was intended to verify the level of first-stage technology developed over the first four years of the 10-year research period. The second and third stages of research are scheduled to be completed by 2022. For phase two, ETRI plans to focus on developing applied technologies and achieving globally competitive performance of QA solutions for expert knowledge including counseling, legal and patent areas. The last phase of the project will focus on developing QA solutions for expert knowledge in both Korean and English so that the AI system can engage in QA activities regarding expert knowledge described in English. In addition, ETRI researchers are committed to developing QA solutions for AI robots and wearable devices that can be utilized with a range of smart devices. Currently, Exobrain shows a level of performance similar to that of Watson, the AI system developed by IBM. In 2011, Watson appeared on the CBS quiz show "Jeopardy!" and defeated human quiz champions. Through further development, this AI system is now supporting the decision-making processes of medical, financial, and legal professionals.  ETRI aims to commercialize Exobrain within the next three years. Exobrain will be used to conduct prior analysis of areas requiring revision of law in partnership with the National Assembly Library, and the AI system is also expected to be used for filtering overlapping technologies in the process of screening patent applications.  "The correct answer rate of Exobrain is 83% on average, which is higher than Watson's performance (70%) in 2011," says Dr. Dong Won Han, Vice President of ETRI, SW and Contents Research Laboratory. "Considering that Exobrain was originally developed for the Korean language, it will have further potential uses when it is upgraded."  About ETRI Established in 1976, ETRI is a non-profit Korean government-funded research organization that has been at the forefront of technological excellence for about 40 years. In the 1980s, ETRI developed TDX (Time Division Exchange) and 4M DRAM. In the 1990s, ETRI commercialized CDMA (Code Division Multiple Access) for the first time in the world. In the 2000s, ETRI developed Terrestrial DMB, WiBro, and 4G LTE Advanced, which became the foundation of mobile communications. Recently, as a global ICT leader, ETRI has been advancing communication and convergence by developing SAN (Ship Area Network) technology, Genie Talk (world class portable automatic interpretation; Korean-English/Japanese/Chinese), and automated valet parking technology. As of 2016, ETRI has about 2,000 employees where about 1,800 of them are researchers. For more informatoin, please visit https://www.etri.re.kr/eng/main/main.etri For more information, please contact Dr. Hyun-ki Kim Director, Knowledge Mining Research Section, ETRI e-mail: [email protected] phone: +82 42 860 5965 Press release distributed by ResearchSEA on behalf of ETRI.


BASEL, Switzerland and WATERTOWN, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid unwanted immunogenicity, have entered into a strategic manufacturing agreement. Under the terms of the agreement, Lonza will produce an Anc80-AAV-based gene therapy product for Selecta’s proprietary program for the treatment of Methylmalonic Acidemia (MMA), a rare inborn error of metabolism, and may in the future produce other Anc80-based products for which Selecta holds exclusive options. This relationship will leverage Lonza’s expertise in the development of robust and industry-scale manufacturing platforms for viral-based products.  Data shows that Anc80-AAV, an in silico-designed synthetic gene therapy vector, has the potential to provide superior gene expression levels in retina, liver, muscle, cochlea’s outer hair cells and other tissue targets in preclinical studies, as well as reduced cross-reactivity as compared to naturally occurring adeno-associated viral vectors (AAVs) that are currently in clinical development. “This agreement with Selecta Biosciences continues to demonstrate Lonza’s leadership position in the cell and gene therapy space,” said Andreas Weiler, Ph.D., Head of Emerging Technologies Business Unit for Lonza’s Pharma&Biotech segment. “Lonza will utilize our extensive cGMP manufacturing knowledge and world-class quality systems to help Selecta Biosciences develop promising novel therapeutics for patients impacted by MMA and other devastating diseases.” “We at Selecta are focused on combining novel and proprietary viral vectors with our immune tolerance Synthetic Vaccine Particles (SVP™) to enable the first non-immunogenic gene therapies, providing the potential for repeat dosing,” said Werner Cautreels, Ph.D., Selecta’s president, CEO and chairman. “We view Lonza – one of the industry’s largest contract manufacturers of biologics and a leading supplier in gene therapy – as an ideal partner. They already have invested in developing various expression technologies, and they share our excitement about Anc80. We look forward to working with them to bring the first Anc80-based program into the clinic as a potential treatment for patients afflicted with MMA.” MMA is an inborn error of metabolism that, according to the National Institutes of Health (NIH), affects an estimated one in 25,000 to 48,000 individuals globally. MMA patients are unable to process certain proteins and fats, leading to the accumulation of toxic metabolites. Symptoms start to develop in early childhood and, despite strict diet, patients suffer from a wide range of disease-related complications such as pancreatitis, strokes and chronic kidney failure. Selecta exclusively licensed Anc80 for MMA from Massachusetts Eye and Ear® (MEE) in May 2016. Under the license agreement, Selecta also has the exclusive option to develop gene therapies using Anc80 for additional pre-defined lysosomal storage, genetic muscular and genetic metabolic diseases. Selecta intends to combine Anc80 with recently discovered transgenes and Selecta’s SVP-Rapamycin to create a novel gene therapy candidate for MMA. This candidate is intended to a) enable the treatment of patients with and without pre-existing anti-AAV antibodies; b) prevent cellular immune responses that often reduce the expression levels of gene therapies; and c) provide the ability to administer repeat gene therapy doses to achieve sufficient levels of methylmalonyl-CoA mutase (MUT), the enzyme that MMA patients are lacking. To advance the MMA program, Selecta entered into a Collaborative Research and Development Agreement (CRADA) with MEE and the National Human Genome Research Institute, NIH, in 2016. Principal investigators in this CRADA initiative are Charles Venditti, MD, PhD, Senior Investigator and Head, Organic Acid Research Section, Medical Genomics and Metabolic Genetics Branch and Luk Vandenberghe, PhD, Director of the Grousbeck Gene Therapy Center at MEE and an Assistant Professor at Harvard Medical School. A physician-scientist specializing in the study of inborn errors of metabolism including MMA, Dr. Venditti and his group have published several studies showing the effectiveness of gene therapy as a treatment for MMA in mice. Dr. Vandenberghe from MEE is the inventor of Anc80. Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid the immune responses that compromise efficacy and lead to life-threatening complications. Selecta is applying its proprietary Synthetic Vaccine Particles (SVP™) to a range of therapeutic areas in which immunogenicity is a key challenge. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat chronic refractory gout patients and reduce their debilitating symptoms, including flares and inflammatory arthritis. Further, Selecta’s two proprietary gene therapy product candidates have the unique potential to enable repeat administration, allowing for dose adjustment in patients and maintenance of therapeutic activity over time. The company is seeking to expand the use of its SVP platform in other areas, such as immuno-oncology, allergies, autoimmune diseases and vaccines. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com. Additional Lonza Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release. Selecta Biosciences, Inc. Disclaimer Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the development of its pipeline, the ability of the company’s SVP platform, including SVP-Rapamycin, to mitigate immune response and create better therapeutic outcomes, the potential treatment applications for products utilizing the SVP platform in areas such as gene therapy, immuno-oncology, allergies, autoimmune diseases and vaccines, whether the company’s proprietary gene therapy product candidates will enable repeat administration, allow for dose adjustment in patients or maintain therapeutic activity over time, the sufficiency of the company’s cash, cash equivalents, investments, and restricted cash and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including their uncertain outcomes, the unproven approach of the company’s SVP technology, undesirable side effects of the company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, substantial fluctuation in the price of its common stock, a significant portion of the company’s total outstanding shares have recently become eligible to be sold into the market, and other important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 10, 2016, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Loading Research Section collaborators
Loading Research Section collaborators